Analysis of drug therapy for disseminated colorectal cancer in outpatient clinical practice
The efficiency of two programs of chemotherapy in the treatment of 46 patients with disseminated colorectal cancer. The programme of chemotherapy of Oxaliplatin + Capecitabine, established authors, with bevacizumabshowed the best results compared with Oxaliplatin + 5-fluorouracyl +leukovorin with bevacizumab. The overall efficiency OXA/5-FU/LV/BEV amounted to 40,91±8,6%, 4,54 ± 5,1% of total regressions. The overall effect of therapy in the OXA/CAP/ BEV amounted to 45,83±8,6%, full regression was achieved in four patients, which amounted to 16,66±5,6%. The median time to progression in the first group of patients was 8.3 months in the second - 9.8 months. Clinical application of involving bevacizumab in combination with different modes of chemotherapy in patients with disseminated colorectal cancer is acceptable and manageable toxicity that doesn’t require reduction of doses.